Latest Observability News

Litchfield Minerals is set to commence a comprehensive airborne magnetic and radiometric survey over its Lucy Creek Project in the Northern Territory, aiming to unlock high-grade manganese potential in an underexplored sedimentary basin.

Alma Metals has unveiled its most extensive and highest-grade copper intersections yet at the Briggs Copper Project, reinforcing confidence in resource expansion and advancing its prefeasibility study plans.

The Swedish Government has formally approved the detailed zoning plan for Talga Group’s Nunasvaara South Graphite Mine, clearing a major regulatory hurdle and advancing the Vittangi Anode Project towards commercial production.

Prodigy Gold NL has reported promising diamond drilling results from its Hyperion Gold Deposit in the Northern Territory, including the first-ever observation of visible gold. These findings reinforce the deposit's potential for further resource growth and underpin upcoming exploration plans.

DTI Group Ltd has responded to an ASX price query following a sharp rise in its share price and trading volume, denying any undisclosed information behind the market activity.

Codrus Minerals reports encouraging initial diamond drilling results at its Bull Run Gold Project in Oregon, while progressing uranium exploration in Canada and executing a significant asset sale in Western Australia.

Riversgold Ltd has affirmed the material significance of its recent Northern Zone gold exploration results alongside a $2 million capital raising, assuring compliance with ASX continuous disclosure rules.

BPM Minerals has reported robust high-grade gold intersections from its maiden drilling at the Beachcomber Prospect within the Forelands Gold Project, Western Australia, confirming a promising south-plunging ore shoot open at depth. The company is gearing up for a follow-up drilling campaign and awaits soil assay results from adjacent targets.

Falcon Metals has reported compelling high-grade gold results from its Blue Moon project in Victoria, extending mineralisation along strike and confirming the potential for a significant new gold reef. The company also advances exploration at Pyramid Hill and Errabiddy while maintaining a strong cash position.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.

Dalaroo Metals is fast-tracking its 2026 exploration program at the Blue Lagoon project in Greenland following promising 2025 results that confirmed widespread rare earth and critical mineralisation. The company aims to define drill-ready targets and advance its position in the strategic critical minerals sector.